Literature DB >> 1751364

Drug-induced agranulocytosis: prognostic factors in a series of 168 episodes.

A Juliá1, M Olona, J Bueno, E Revilla, J Rosselló, J Petit, M Morey, A Flores, L Font, J Maciá.   

Abstract

The prognostic value of 36 clinical and analytical parameters at diagnosis in patients with drug-induced agranulocytosis was analysed in an adult population. This multicentre, retrospective study examined possible prognostic factors by multiple logistic regression analysis in a series of 168 clinical episodes. The overall mortality was 16%. Renal insufficiency at diagnosis and the development of bacteraemia were associated with a poor prognosis. Advanced age, decreased leucocyte count, lymphocytopenia, bone marrow myeloid hypoplasia, increased percentage of bone marrow plasma cells and shock were found to be associated with a poor prognosis only in the univariate analysis. An independent analysis of the myeloid cellularity at diagnosis showed an inverse correlation with the time to recovery of the granulocyte counts (r = -0.43; P = 0.001). Our data indicate that despite some important clinical differences (higher incidence of infections of the oropharynx, shorter period of neutropenia and almost exclusive presence of gram-negative organisms), the infections complicating the treatment of cancer patients have the same prognostic features than those seen in patients with acute agranulocytosis. Therefore the established therapeutic guidelines for neutropenia after cancer chemotherapeutic agents are applicable to patients with acute agranulocytosis.

Entities:  

Mesh:

Year:  1991        PMID: 1751364     DOI: 10.1111/j.1365-2141.1991.tb08042.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  22 in total

1.  Severe neutropenia: a diagnostic approach.

Authors:  H G Munshi; R B Montgomery
Journal:  West J Med       Date:  2000-04

Review 2.  Drug-induced myelosuppression : diagnosis and management.

Authors:  Peter J Carey
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

3.  Detection and incidence of drug-induced agranulocytosis in hospital: a prospective analysis from laboratory signals.

Authors:  N Tavassoli; E Duchayne; B Sadaba; K Desboeuf; A Sommet; M Lapeyre-Mestre; M J Muoz; P Sie; J Honorato; J L Montastruc; H Bagheri
Journal:  Eur J Clin Pharmacol       Date:  2007-01-17       Impact factor: 2.953

Review 4.  How we diagnose neutropenia in the adult and elderly patient.

Authors:  Jan Palmblad; Carlo Dufour; Helen A Papadaki
Journal:  Haematologica       Date:  2014-07       Impact factor: 9.941

5.  Pure white cell aplasia and health food products.

Authors:  P D Forsyth; J M Davies
Journal:  Postgrad Med J       Date:  1995-09       Impact factor: 2.401

6.  Treatment of drug-induced agranulocytosis with recombinant granulocyte colony-stimulating factor (rh G-CSF).

Authors:  A Willfort; C Lorber; S Kapiotis; S Sertl; R Hainz; P Kirchweger; U Jäger; P A Kyrle; K Lechner; K Geissler
Journal:  Ann Hematol       Date:  1993-05       Impact factor: 3.673

7.  Novel use of granulocyte colony stimulating factor as an adjunct for treatment of schizoaffective disorder complicated by sodium valproate induced agranulocytosis.

Authors:  S Subbarayan; S Thomas; M George
Journal:  Indian J Psychiatry       Date:  2012-07       Impact factor: 1.759

Review 8.  Life-threatening idiosyncratic drug-induced agranulocytosis in elderly patients.

Authors:  Emmanuel Andrès; Esther Noel; Jean-Emmanuel Kurtz; Nourredine Henoun Loukili; Georges Kaltenbach; Frédéric Maloisel
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 9.  Idiosyncratic drug-induced haematological abnormalities. Incidence, pathogenesis, management and avoidance.

Authors:  W N Patton; S B Duffull
Journal:  Drug Saf       Date:  1994-12       Impact factor: 5.606

10.  Risks of rhG-CSF treatment in drug-induced agranulocytosis.

Authors:  H Demuynck; P Zachée; G E Verhoef; M Schetz; G Van den Berghe; P Lauwers; M A Boogaerts
Journal:  Ann Hematol       Date:  1995-03       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.